Related Experiment Video
Updated: May 15, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
FDA approves Datroway: a novel therapy for HR-positive, HER2-negative metastatic breast cancer
1Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
Abstract:
The Food and Drug Administration (FDA) has approved datopotamab deruxtecan (Datroway) for the treatment of unresectable or metastatic HR-positive, HER2-negative breast cancer. This antibody-drug conjugate comprises a monoclonal antibody (mAb) that targets TROP2, a cytotoxic agent DXd, and a linker. The mAb binds to TROP2 on cancer cells, facilitating internalization, after which DXd is released, inducing cell death. In the TROPION-Breast01 trial, datopotamab deruxtecan demonstrated superiority over conventional chemotherapy. It provides a promising alternative for patients who have failed prior endocrine or chemotherapy, offering enhanced efficacy than traditional treatments. However, additional studies are required to thoroughly assess the drug's safety and efficacy, as well as to establish the most current information regarding its optimal dosage and administration guidelines.
Insights
Datopotamab deruxtecan (Datroway) is now FDA-approved for HR-positive, HER2-negative metastatic breast cancer. This novel TROP2-targeting antibody-drug conjugate shows improved efficacy over chemotherapy in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer represents a significant portion of breast cancer diagnoses.
- Treatment resistance to endocrine therapy and chemotherapy is a clinical challenge in advanced HR+/HER2- breast cancer.
- Targeted therapies, such as antibody-drug conjugates, offer new treatment modalities.
Purpose of the Study:
- To evaluate the efficacy and safety of datopotamab deruxtecan in patients with unresectable or metastatic HR+/HER2- breast cancer.
- To compare datopotamab deruxtecan against physician's choice of conventional chemotherapy.
- To establish datopotamab deruxtecan as a potential new treatment option for this patient population.
Main Methods:
- The TROPION-Breast01 trial was a randomized, open-label study.
- Patients received either datopotamab deruxtecan or physician's choice of chemotherapy.
- Primary endpoint was progression-free survival (PFS).
Main Results:
- Datopotamab deruxtecan demonstrated statistically significant superiority in progression-free survival compared to conventional chemotherapy.
- The antibody-drug conjugate showed a favorable safety profile, though further assessment is ongoing.
- Objective response rates were also higher in the datopotamab deruxtecan arm.
Conclusions:
- Datopotamab deruxtecan is an effective and promising new treatment for patients with previously treated unresectable or metastatic HR+/HER2- breast cancer.
- It offers a valuable alternative to chemotherapy, potentially improving patient outcomes.
- Further research is warranted to fully elucidate long-term safety, efficacy, and optimal dosing strategies.
